Analysts Set CRISPR Therapeutics AG (NASDAQ:CRSP) PT at $64.24

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have received an average recommendation of “Hold” from the eighteen ratings firms that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell recommendation, six have issued a hold recommendation and ten have given a buy recommendation to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $64.2353.

A number of research firms recently weighed in on CRSP. Chardan Capital increased their price objective on shares of CRISPR Therapeutics from $74.00 to $76.00 and gave the stock a “buy” rating in a research report on Saturday, February 14th. Evercore reiterated an “outperform” rating and issued a $74.00 price target on shares of CRISPR Therapeutics in a report on Friday, February 13th. TD Cowen raised their price target on CRISPR Therapeutics from $40.00 to $45.00 and gave the stock a “hold” rating in a research note on Friday, February 13th. Citigroup restated a “buy” rating on shares of CRISPR Therapeutics in a report on Monday, February 16th. Finally, Morgan Stanley reiterated an “underweight” rating and issued a $33.00 target price on shares of CRISPR Therapeutics in a research note on Tuesday, February 17th.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 6,967 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $52.58, for a total value of $366,324.86. Following the completion of the sale, the chief executive officer owned 226,106 shares in the company, valued at approximately $11,888,653.48. The trade was a 2.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel James R. Kasinger sold 2,112 shares of the stock in a transaction that occurred on Thursday, February 19th. The stock was sold at an average price of $52.58, for a total value of $111,048.96. Following the completion of the transaction, the general counsel directly owned 85,115 shares in the company, valued at approximately $4,475,346.70. This trade represents a 2.42% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 99,079 shares of company stock valued at $5,643,674 in the last quarter. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Virtu Financial LLC purchased a new position in shares of CRISPR Therapeutics during the fourth quarter valued at $862,000. Mcguire Capital Advisors Inc. bought a new position in CRISPR Therapeutics during the 4th quarter worth about $25,000. Axxcess Wealth Management LLC increased its position in CRISPR Therapeutics by 6.2% during the 4th quarter. Axxcess Wealth Management LLC now owns 13,022 shares of the company’s stock valued at $683,000 after purchasing an additional 764 shares during the period. Corient Private Wealth LLC raised its holdings in shares of CRISPR Therapeutics by 5.7% in the 4th quarter. Corient Private Wealth LLC now owns 8,566 shares of the company’s stock valued at $449,000 after purchasing an additional 460 shares in the last quarter. Finally, Jacobs Equity LLC bought a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at about $634,000. Institutional investors own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

Shares of CRISPR Therapeutics stock opened at $60.00 on Thursday. The stock has a 50 day moving average price of $54.20 and a 200-day moving average price of $57.31. CRISPR Therapeutics has a one year low of $30.04 and a one year high of $78.48. The stock has a market cap of $5.76 billion, a price-to-earnings ratio of -9.20 and a beta of 1.72.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Thursday, February 12th. The company reported ($1.37) earnings per share for the quarter, missing the consensus estimate of ($1.15) by ($0.22). The firm had revenue of $0.86 million during the quarter, compared to analysts’ expectations of $4.72 million. CRISPR Therapeutics had a negative net margin of 16,569.77% and a negative return on equity of 26.31%. The company’s revenue was down 97.8% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.01) EPS. Sell-side analysts predict that CRISPR Therapeutics will post -5.16 earnings per share for the current fiscal year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.